Previous this yr, my colleague Yasmin Tayag wrote that Ozempic—the diabetes drug that has change into a cultural phenomenon in its off-label use for weight-loss—used to be about to be previous information. She used to be proper.

Over the last few days, shows on the American Diabetes Affiliation assembly in San Diego have delivered a slew of findings that counsel the Age of Ozempic is already over. Taking its position: a parade of higher remedies for weight problems. A brand new, oral type of semaglutide works about in addition to Ozempic or Wegovy, that are injectable variations of the similar; so does any other tablet containing a drug referred to as orforglipron. New information additionally trace that photographs containing tirzepatide or survodutide might finally end up running higher than semaglutide, and {that a} compound referred to as retatrutide is in all probability the absolute best of all, with results coming near the ones of bariatric surgical operation. I received’t even bore you with the inside track about pemvidutide, lotiglipron, and danuglipron!

Learn: We’ve had a inexpensive, stronger Ozempic selection for many years

In different phrases, Ozempic is previous information, and faster than we idea. The drug will nonetheless be widely-used, however a bewildering array of medicines for weight problems is advancing via construction, and within the coming years, they’re going to change into a bewildering array of choices for sufferers: Some medicine could also be inexpensive or extra handy than the others; some could also be more potent; some might ultimately have fewer nasty unintended effects or extra constant advantages around the inhabitants. That handiest makes it extra worrying that, even because the drug Ozempic is changing into out of date, the identify Ozempic, because the shorthand for a category of substances, turns out destined to survive.

For months now, the phrase has been used as a generic time period, alongside the traces of Band-Help, escalator, and thermos: a selected emblem that will get reshaped via not unusual use into a kind. Believe the entire headlines concerning the new “Ozempic drugs,” the approaching of “Ozempic-like medicine,” or the spreading hype for “Nature’s Ozempic.” See reporting at the scourges of Ozempic face, Ozempic finger, Ozempic burps, Ozempic butts. This may all be high-quality if the medicine had been roughly the similar, in the best way that Kleenex facial tissues are beautiful very similar to Puffs. However they’re now not, and pretending differently may have a value.

Learn: Did scientists unintentionally invent an anti-addiction drug?

It’s true that each one of those medicine are very similar to some extent. The experiences from San Diego describe a collection of medicines with a minimum of one not unusual supply of motion: They every serve to turn on a receptor for a hormone referred to as GLP-1, which stifles urge for food and reasons insulin to be launched (amongst different physically results). Liraglutide used to be the primary such drug to be authorized as a remedy for weight problems, and has been to be had for that use since 2014. Some other drug that hits the similar receptor, dulaglutide, has additionally been to be had to regard diabetes for years. Semaglutide arrived a couple of years later, first as a shot for diabetes (Ozempic), then in tablet shape (Rybelsus), and in the end as a higher-dose injection that used to be authorized for weight reduction (Wegovy). Extra medicine of this sort however comprised of smaller molecules (and inexpensive to supply) are within the works, together with two of the brand new “Ozempic drugs,” orforglipron and danuglipron. Any of those GLP-1-targeting medicine can suppress your need to consume, resulting in a minimum of some lack of weight. Any of them may come up with nausea, abdomen ache, and diarrhea. In that sense, they’re all certainly Ozemp-ish. However they don’t seem to be Ozempic.

Different medicine that get squeezed below the Ozempic umbrella do different issues. Mounjaro accommodates tirzepatide, which turns on the GLP-1 receptor like the opposite medicine but additionally any other receptor for a hormone referred to as GIP. Survodutide, one of the vital medicine introduced over the weekend in San Diego, goals each GLP-1 and glucagon receptors. Retatrutide, in all probability the maximum promising of the weight problems drugs now within the pipeline, turns on GLP-1, GIP, and glucagon receptors. Do those medicine impact the similar extensive machine of so-called incretin hormones as Ozempic? Positive. Do they result in weight reduction? Very a lot so. Can they dissatisfied your abdomen to an uncomfortable stage? After all. However they’re much less like siblings of Ozempic than cousins.

“Those medicine have other houses,” Fatima Cody Stanford, an obesity-medicine doctor at Massachusetts Basic Health center and Harvard Scientific College, informed me. “They have got other mechanisms of motion.” Semaglutide limits glucagon secretion, as an example, while tirzepatide’s results on glucagon appear to head in each instructions. Stanford says the latter drug does extra to switch the frame’s cholesterol levels. In the longer term, such distinctions will assist resolve how those new medicine are compatible in combination to outline the way forward for weight problems remedy. Preferably, sufferers and their medical doctors will talk about the professionals and cons of every.

Trademark attorneys have a ghoulish identify for when a emblem turns into synonymous with a product elegance, as when Kleenex changed into a not unusual time period for tissues: They name it genericide. The attorneys have a tendency to peer this phenomenon during the catastrophic body of misplaced IP—a billion-dollar emblem identify up in smoke. Advertising and marketing mavens might view it from the opposite facet, as a contented sign that the logo identify has accomplished general marketplace domination. With Ozempic, although, the trademark has been stretched to this point that it’s actively deceptive. Believe if Kleenex weren’t only a not unusual identify for facial tissues, but additionally one for snot-sucking vacuum tubes and hand held equipment for selecting boogers. The confusion that ensues is borne by means of the shopper. “It units up false expectancies,” says Ted Kyle, a pharmacist and an obesity-policy advisor who’s on the assembly in San Diego. It really works towards the pursuits of the affected person.

“We might by no means do that with any other illness,” Stanford mentioned. If Ozempic had been, say, a type of most cancers immunotherapy and now not a drug for diabetes and weight problems, we wouldn’t make its identify generic, she asserted: “We’d by no means say, ‘Oh glance, there’s any other Ozempic-like remedy for most cancers.’” In her view, the truth that we do say such issues about weight problems—that the entire new weight problems meds are “Ozempic drugs” or “Ozempic-like” photographs—demonstrates a overlook for the subtleties of the situation. “It’s differently to shortchange or simplify weight problems,” she mentioned. It leaves us caught in an previous, superseded mindset the place the main points are smoothed over: Devour much less and workout extra, and perhaps take the weight-loss drug till you’re higher.

There’s, in fact, some distinctive feature in simplicity. I referenced 10 other medicine on this tale and will pronounce handiest part of them. (Simply attempt to say orforglipron. It seems like an onomatopoeia for the unintended effects of orforglipron.) However in a post-Ozempic generation, calling the entirety Ozempic handiest makes the issue two times as dangerous. It oversimplifies weight problems whilst making remedies extra complicated. It gives up a bottle stuffed with magic drugs however doesn’t let you know which is which.